FindTrial
Sign In

Effects of cardioconversion therapy for intraoperative new-onset atrial fibrillation on the course of postoperative atrial fibrillation and prognosis in patients undergoing thoracic surgery

Effects of cardioconversion therapy for intraoperative new-onset atrial fibrillation on the course of postoperative atrial fibrillation and prognosis in patients undergoing thoracic surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INQ-17013286
Enrollment
Unknown
Registered
2017-11-08
Start date
2017-12-01
Completion date
Unknown
Last updated
2017-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation

Interventions

atrial fibrillation with cardioconversion therapy:cardioconversion
atrial fibrillation without cardioconversion:no
non-atrial fibrillation:no

Sponsors

Shanghai Chest Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients aged 60 to 80 years, undergoing radical operation for lung or esophageal cancer, intraoperative new-onset atrial fibrillation associated with the surgical maneuvers.

Exclusion criteria

Exclusion criteria: Patients with preoperative severe cardiocerebral-vascular disease, 3 degree hypertension, severe hepatal or renal dysfunction, arrhythmia, taking arrhythmic drugs, perioperative severe unexpected accident, atrial fibrillation induced by other causes.

Design outcomes

Primary

MeasureTime frame
postoperative atrial fibrillation course;—

Secondary

MeasureTime frame
Morbidity during postoperative 30 days;Mortality during postoperative 30 days;—

Countries

China

Contacts

Public ContactDehua WU

Shanghai Chest Hospital

wudehua74@163.com+86 13671684120

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026